Non-clear cell renal cell carcinoma, part 2: therapy.

Non-clear cell renal cell carcinomas (RCCs) represent a heterogeneous group of diseases with distinct molecular drivers, histologies, and clinical outcomes. Their low incidence and heterogeneity have resulted in a lack of studies that address the optimal strategies for each subtype. This article (the second in a 2-part series) reviews the current targeted therapies approved for RCC, such as the vascular endothelial growth factor receptor tyrosine kinase inhibitors and the mammalian target of rapamycin inhibitors. Ongoing studies will provide more information regarding the role of these agents in non-clear cell RCC. Ultimately, enhanced understanding of genetic triggers and the development of more tailored treatments remain imperative to improve outcomes in non-clear cell RCC.

[1]  S. Signoretti,et al.  A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma. , 2015 .

[2]  T. Choueiri,et al.  Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2014, European urology.

[3]  T. Choueiri,et al.  First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2014, Clinical genitourinary cancer.

[4]  M. Dimopoulos,et al.  Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study. , 2014, Clinical genitourinary cancer.

[5]  G. Freeman,et al.  PD-L1 expression in nonclear-cell renal cell carcinoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  S. Signoretti,et al.  RNA-seq Reveals Aurora Kinase–Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma , 2014, Molecular Cancer Research.

[7]  T. Powles,et al.  809OIMMUNE CORRELATES AND LONG TERM FOLLOW UP OF A PHASE IA STUDY OF MPDL3280A, AN ENGINEERED PD-L1 ANTIBODY, IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Tae Min Kim,et al.  Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Max Costa,et al.  Chromatin Memory in the Development of Human Cancers , 2014, Gene technology.

[10]  E. Porfiri,et al.  Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib. , 2014, Clinical genitourinary cancer.

[11]  W. Kaelin,et al.  A phase I study of cabozantinib (XL184) in patients with renal cell cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Ro̸rth,et al.  Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre , 2014, Scandinavian journal of urology.

[13]  G. Bartsch,et al.  HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A , 2014, Molecular Cancer.

[14]  R. Motzer,et al.  Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. , 2014 .

[15]  P. Tamboli,et al.  Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial. , 2014 .

[16]  E. Plimack,et al.  Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat. , 2014 .

[17]  A. Kibel,et al.  Cytoreductive nephrectomy in patients with metastatic non‐clear‐cell renal cell carcinoma (RCC) , 2014, BJU international.

[18]  C. Wood,et al.  Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy , 2014, World Journal of Urology.

[19]  N. Rioux-Leclercq,et al.  MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array , 2014, Clinical Cancer Research.

[20]  R. Motzer,et al.  Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  M. Colecchia,et al.  Treatment of collecting duct carcinoma: current status and future perspectives. , 2014, Anticancer research.

[22]  R. Berger,et al.  Patients with metastatic papillary renal cell carcinoma (RCC) who may benefit from sunitinib therapy (tx): Results from an international metastatic RCC database. , 2014 .

[23]  Y. Allory,et al.  Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  C. Ricketts,et al.  Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma , 2013, Clinical Epigenetics.

[25]  T. Choueiri,et al.  Targeting the Hepatocyte Growth Factor/c-Met Signaling Pathway in Renal Cell Carcinoma , 2013, Cancer journal.

[26]  T. Powles,et al.  Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). , 2013 .

[27]  David C. Smith,et al.  Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. , 2013 .

[28]  Liangren Liu,et al.  Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature , 2013, International Urology and Nephrology.

[29]  Y. Koh,et al.  Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Jia-hong Dong,et al.  Papillary carcinoma of the duodenum combined with right renal carcinoma: a case report , 2013, World Journal of Surgical Oncology.

[31]  Keith T Flaherty,et al.  Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Vercelli,et al.  Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study. , 2012, Future oncology.

[33]  G. Demetri,et al.  Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors , 2012, Cancer.

[34]  Lisa L. Smith,et al.  A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. , 2012, European urology.

[35]  A. Ravaud,et al.  First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Ahn,et al.  Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  I. Sinelnikov,et al.  Phase II, Multicenter, Uncontrolled Trial of Single-agent Capecitabine in Patients With Non-clear Cell Metastatic Renal Cell Carcinoma , 2012, American journal of clinical oncology.

[38]  J. Manola,et al.  A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 , 2012, Medical Oncology.

[39]  A. Sato,et al.  Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically , 2012, BJU international.

[40]  J. Ellinger,et al.  Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma. , 2012, Anticancer research.

[41]  H. Drabkin,et al.  Phase I trial of the HDAC inhibitor LBH589 in combination with sorafenib in patients with renal cell carcinoma, non-small cell lung cancer and soft tissue sarcomas. , 2012, Journal of Clinical Oncology.

[42]  J. Machiels,et al.  An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. , 2012, European journal of cancer.

[43]  V. Reuter,et al.  Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma , 2012, Investigational New Drugs.

[44]  H. Moch,et al.  Complete remission of pulmonary metastases of Bellini duct carcinoma with cisplatin, gemcitabine and bevacizumab , 2012, The American journal of case reports.

[45]  J. Jónasson,et al.  Indications and Surgical Outcome Following Pulmonary Metastasectomy: A Nationwide Study , 2012, Thoracic and Cardiovascular Surgeon.

[46]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[47]  J. Dutcher,et al.  Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy , 2011, Medical oncology.

[48]  N. Senzer,et al.  A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors , 2011, Clinical Cancer Research.

[49]  D. Steinbrüchel,et al.  Outcome after Pulmonary Metastasectomy: Analysis of 5 Years Consecutive Surgical Resections 2002–2006 , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[50]  E. Jonasch,et al.  A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma , 2011, BJU international.

[51]  A. Ravaud,et al.  Combination of Gemcitabine and Doxorubicin in Rapidly Progressive Metastatic Renal Cell Carcinoma and/or Sarcomatoid Renal Cell Carcinoma , 2011, Oncology.

[52]  D. Collins,et al.  Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  M. Mazumdar,et al.  NCI 6896: A phase I trial of suberoylanilide hydroxamic acid (SAHA) and 13-cis retinoic acid in the treatment of patients with advanced renal cell carcinoma (RCC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  P. Tamboli,et al.  Vascular endothelial growth factor‐targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma , 2010, Cancer.

[55]  Norbert Hollaender,et al.  Phase 3 trial of everolimus for metastatic renal cell carcinoma , 2010, Cancer.

[56]  M. Bader,et al.  Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell Carcinoma: a prospective evaluation , 2010, European journal of medical research.

[57]  Gong-hui Li,et al.  Metachronous contralateral testicular and bilateral adrenal metastasis of chromophobe renal cell carcinoma: a case report and review of the literature , 2010, Journal of Zhejiang University SCIENCE B.

[58]  J. Hajdenberg,et al.  Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America , 2010, Cancer.

[59]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  D. Fisher,et al.  Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. , 2010, Cancer research.

[61]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  T. Choueiri,et al.  A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. , 2009, Clinical genitourinary cancer.

[63]  C. Porta,et al.  Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. , 2009, The Lancet. Oncology.

[64]  Apurva A Desai,et al.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  R. Figlin,et al.  Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies , 2009, Medical oncology.

[66]  A. Belldegrun,et al.  Pathobiology and prognosis of chromophobe renal cell carcinoma. , 2008, Urologic oncology.

[67]  H. Date,et al.  Pulmonary resection for metastasis from renal cell carcinoma. , 2008, Interactive cardiovascular and thoracic surgery.

[68]  A. Belldegrun,et al.  Performance status and cytoreductive nephrectomy , 2008, Cancer.

[69]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[70]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[71]  S. Culine,et al.  Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. , 2007, The Journal of urology.

[72]  J. Cheville,et al.  PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[73]  K. Grankvist,et al.  Different vascular endothelial growth factor (VEGF), VEGF‐receptor 1 and ‐2 mRNA expression profiles between clear cell and papillary renal cell carcinoma , 2006, BJU international.

[74]  C. Ng,et al.  Phase I study of low-dose hypomethylating agent azacitidine (5-AC) combined with the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced cancers. , 2006, Journal of Clinical Oncology.

[75]  Robert E. Brown,et al.  Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. , 2006, Annals of clinical and laboratory science.

[76]  Y. Nagashima,et al.  Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. , 2006, Cancer research.

[77]  D. Bottaro,et al.  Hereditary papillary renal carcinoma type I. , 2004, Current molecular medicine.

[78]  M. Milowsky,et al.  Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma , 2004, Cancer.

[79]  G. Freeman,et al.  PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[80]  G. Landberg,et al.  Expression of vascular endothelial growth factor protein in human renal cell carcinoma , 2004, BJU international.

[81]  S. Culine,et al.  Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. , 2002, The Journal of urology.

[82]  R. Motzer,et al.  Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  Holger Moch,et al.  VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma , 2002, The Journal of pathology.

[84]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[85]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[86]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[87]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[88]  D. Petrylak,et al.  Cytotoxic chemotherapy for advanced renal cell carcinoma. , 1993, The Urologic clinics of North America.

[89]  G. Freeman,et al.  PD-L 1 expression in nonclear-cell renal cell carcinoma , 2014 .

[90]  H. Drabkin,et al.  Phase I trial of the HDAC inhibitor LBH589 in combination with sorafenib in patients with renal cell carcinoma, non-small cell lung cancer and soft tissue sarcomas. , 2012, Journal of Clinical Oncology.

[91]  C. Blank,et al.  Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: Subgroup analysis of REACT. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  M. Gordon Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Therapy , 2009 .

[93]  M. Gordon Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma , 2009 .

[94]  M. Gordon,et al.  Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .